Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating update from TD Cowen analyst Steve Scala on November 4, who maintained a Hold rating on the stock and set a $30 price target.
Pfizer Inc. reported its fiscal Q3 2025 results the same day, announcing that revenue for the quarter experienced a 7% year-over-year operational decline to $16.7 billion. The operational decrease was attributed to a year-over-year decline in COVID-19 product revenues, primarily because of lower infection rates affecting the demand for Paxlovid along with a “narrower” vaccine recommendation for COVID-19 in the United States, reducing the eligible population for Comirnaty. However, strengthening commercial execution led to a 4% operational revenue growth of the non-COVID portfolio.
The company further reported that fiscal Q3 2025 diluted EPS was $0.62, and adjusted diluted EPS reached $0.87. Management reaffirmed the full-year 2025 revenue guidance in the $61.0 to $64.0 billion range, and raised and narrowed adjusted diluted EPS guidance to a range of $3.00 to $3.15 from $2.90 to $3.10 previously.
Management stated that the updated adjusted diluted EPS guidance factors in the company’s solid year-to-date performance, progress with ongoing cost improvement initiatives, continued confidence in the business, and improvement in its effective tax rate.
Pfizer Inc. is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
